$PHIO
Phio Pharmaceuticals Corp.

2013 Q2 Form 10-Q Financial Statement

#000119312513220846 Filed on May 15, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2013 Q1 2012 Q4
Revenue $225.0K $53.00K $40.00K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin -$11.27M $12.93M $620.0K
YoY Change -1665.28% 1624.0% -34.04%
% of Gross Profit
Research & Development $1.213M $13.77M $1.140M
YoY Change -82.54% 1093.33% -26.45%
% of Gross Profit
Depreciation & Amortization $20.00K $26.00K $30.00K
YoY Change -50.0% -35.0% -25.0%
% of Gross Profit
Operating Expenses $2.190M $14.45M $1.750M
YoY Change -71.42% 658.37% -29.72%
Operating Profit -$1.965M -$14.39M
YoY Change -74.36% 655.59%
Interest Expense $4.000K $0.00 $0.00
YoY Change -140.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00 -$3.000K $0.00
YoY Change -100.0% -400.0% -100.0%
Pretax Income -$1.960M -$14.40M -$1.710M
YoY Change -74.21% 646.11% -30.2%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.961M -$14.40M -$1.710M
YoY Change -74.19% 647.51% -30.2%
Net Earnings / Revenue -871.56% -27164.15% -4275.0%
Basic Earnings Per Share
Diluted Earnings Per Share $1.325B -$15.20B -$2.334B
COMMON SHARES
Basic Shares Outstanding 338.2M shares 321.6M shares 158.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2013 Q1 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.59M $19.64M $5.130M
YoY Change 132.06% 5355.56% 926.0%
Cash & Equivalents $8.587M $19.64M $5.127M
Short-Term Investments $9.000M
Other Short-Term Assets $260.0K $150.0K $260.0K
YoY Change 62.5% 150.0% 8.33%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $17.85M $19.80M $5.392M
YoY Change 130.61% 1860.2% 302.69%
LONG-TERM ASSETS
Property, Plant & Equipment $147.0K $172.0K $198.0K
YoY Change -47.5% -46.25% -44.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $0.00
YoY Change
Total Long-Term Assets $147.0K $174.0K $200.0K
YoY Change -47.5% -45.63% -43.66%
TOTAL ASSETS
Total Short-Term Assets $17.85M $19.80M $5.392M
Total Long-Term Assets $147.0K $174.0K $200.0K
Total Assets $18.00M $19.97M $5.592M
YoY Change 124.39% 1401.65% 230.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $358.0K $366.0K $416.0K
YoY Change 27.86% -51.2% 7.49%
Accrued Expenses $913.0K $1.126M $767.0K
YoY Change 49.67% 108.52% 40.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0% -66.67%
Total Short-Term Liabilities $1.510M $1.958M $1.679M
YoY Change 10.22% -6.76% -5.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $0.00 $0.00 $30.00K
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $30.00K
YoY Change -100.0% -100.0% -94.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.510M $1.958M $1.679M
Total Long-Term Liabilities $0.00 $0.00 $30.00K
Total Liabilities $1.510M $1.958M $1.706M
YoY Change 10.22% -36.84% -25.21%
SHAREHOLDERS EQUITY
Retained Earnings $17.16M
YoY Change
Common Stock $1.000K $32.00K $16.00K
YoY Change 60.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.715M $8.118M -$5.840M
YoY Change
Total Liabilities & Shareholders Equity $18.00M $19.97M $5.592M
YoY Change 124.39% 1401.65% 230.11%

Cashflow Statement

Concept 2013 Q2 2013 Q1 2012 Q4
OPERATING ACTIVITIES
Net Income -$1.961M -$14.40M -$1.710M
YoY Change -74.19% 647.51% -30.2%
Depreciation, Depletion And Amortization $20.00K $26.00K $30.00K
YoY Change -50.0% -35.0% -25.0%
Cash From Operating Activities -$2.050M -$1.128M -$1.150M
YoY Change 41.38% -6.7% -59.07%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K
YoY Change -100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities -$9.000M $10.00K
YoY Change -120.0%
Cash From Investing Activities -$9.000M $10.00K
YoY Change 89900.0% -116.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $15.65M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 15.64M 0.000
YoY Change -99.88% 1448.91% -100.0%
NET CHANGE
Cash From Operating Activities -2.050M -1.128M -1.150M
Cash From Investing Activities -9.000M 10.00K
Cash From Financing Activities 10.00K 15.64M 0.000
Net Change In Cash -11.04M 14.52M -1.140M
YoY Change -253.12% -7394.47% -1525.0%
FREE CASH FLOW
Cash From Operating Activities -$2.050M -$1.128M -$1.150M
Capital Expenditures $0.00 -$10.00K
Free Cash Flow -$2.050M -$1.128M -$1.140M
YoY Change 42.36% -6.7% -59.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1958000
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
338153834 shares
CY2006Q2 us-gaap Stockholders Equity
StockholdersEquity
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
112956911 shares
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.145
CY2011Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
304000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11983000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.12
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2013Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
102000
CY2013Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
53000
CY2013Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
464000
CY2013Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
10000000
CY2013Q1 us-gaap Assets
Assets
19972000
CY2013Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
10053000
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19643000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.10
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
63847938 shares
CY2013Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
9896 shares
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19972000
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
321627134 shares
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
32000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
9053544 shares
CY2013Q1 us-gaap Liabilities
Liabilities
1958000
CY2013Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2000
CY2013Q1 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
9896000
CY2013Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
2000
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47967499000 shares
CY2013Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1126000
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
172000
CY2013Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
321627134 shares
CY2013Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000 shares
CY2013Q1 us-gaap Assets Current
AssetsCurrent
19798000
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
39640000
CY2013Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
9896 shares
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2013Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
9896000
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
8118000
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1540000
CY2013Q1 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
31554000
CY2013Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
366000
CY2002Q4 us-gaap Stockholders Equity
StockholdersEquity
CY2003Q4 us-gaap Stockholders Equity
StockholdersEquity
-89000
CY2004Q4 us-gaap Stockholders Equity
StockholdersEquity
-968000
CY2005Q4 us-gaap Stockholders Equity
StockholdersEquity
-450000
CY2006Q4 us-gaap Stockholders Equity
StockholdersEquity
-268000
CY2007Q4 us-gaap Stockholders Equity
StockholdersEquity
10823000
CY2008Q4 us-gaap Stockholders Equity
StockholdersEquity
8968000
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
741000
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
2430000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
503000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-587000
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1679000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
212000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
53000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
491000
CY2012Q4 us-gaap Assets
Assets
5592000
CY2012Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
53000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5127000
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
27000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.10
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
63847938 shares
CY2012Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
9726 shares
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5592000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
158670223 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2012Q4 us-gaap Liabilities
Liabilities
1706000
CY2012Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2000
CY2012Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
9726000
CY2012Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
5000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
767000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
198000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
158670223 shares
CY2012Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000 shares
CY2012Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
9726 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Assets Current
AssetsCurrent
5392000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11301000
CY2012Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
9726000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-5840000
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
17157000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
416000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16400000
CY2013Q1 rxii Net Proceeds From Issuance Of Common Stock
NetProceedsFromIssuanceOfCommonStock
15600000
rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
2000
CY2011Q3 us-gaap Stock Issued During Period Value Issued For Noncash Considerations
StockIssuedDuringPeriodValueIssuedForNoncashConsiderations
1.00
CY2011Q3 us-gaap Stock Issued During Period Shares Issued For Cash
StockIssuedDuringPeriodSharesIssuedForCash
100 shares
CY2003 us-gaap Net Income Loss
NetIncomeLoss
-89000
CY2005 us-gaap Net Income Loss
NetIncomeLoss
-2209000
CY2005 rxii Net Transactions With Parent
NetTransactionsWithParent
2727000
CY2006 us-gaap Net Income Loss
NetIncomeLoss
-2405000
CY2006 rxii Net Transactions With Parent
NetTransactionsWithParent
2587000
CY2007 us-gaap Net Income Loss
NetIncomeLoss
-10990000
CY2007 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
15679000
CY2007 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
4318000
CY2007 rxii Adjustments To Divisional Equity Share Based Compensation Requisite Service Period Recognition Value
AdjustmentsToDivisionalEquityShareBasedCompensationRequisiteServicePeriodRecognitionValue
1814000
CY2009 us-gaap Net Income Loss
NetIncomeLoss
-18387000
CY2009 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
7714000
CY2009 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
-1756000
CY2009 rxii Adjustments To Divisional Equity Share Based Compensation Requisite Service Period Recognition Value
AdjustmentsToDivisionalEquityShareBasedCompensationRequisiteServicePeriodRecognitionValue
4202000
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-11993000
CY2010 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
11640000
CY2010 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
-2326000
CY2010 rxii Adjustments To Divisional Equity Share Based Compensation Requisite Service Period Recognition Value
AdjustmentsToDivisionalEquityShareBasedCompensationRequisiteServicePeriodRecognitionValue
4368000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
122000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-2537000
CY2011 rxii Reclassification Of Derivative Liability Upon Elimination Of Obligation
ReclassificationOfDerivativeLiabilityUponEliminationOfObligation
9249000
CY2011 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
1500000
CY2011 rxii Cash Contributions To Parent Company
CashContributionsToParentCompany
369000
CY2011 rxii Adjustments To Additional Paid In Capital Expenses Paid By Parent Company
AdjustmentsToAdditionalPaidInCapitalExpensesPaidByParentCompany
2058000
CY2011 rxii Net Income Loss Attributable To Predecessor Company
NetIncomeLossAttributableToPredecessorCompany
-7682000
CY2011 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
-8083000
CY2011 rxii Adjustments To Divisional Equity Share Based Compensation Requisite Service Period Recognition Value
AdjustmentsToDivisionalEquityShareBasedCompensationRequisiteServicePeriodRecognitionValue
1987000
CY2004 us-gaap Net Income Loss
NetIncomeLoss
-3272000
CY2004 rxii Net Transactions With Parent
NetTransactionsWithParent
2393000
CY2008 us-gaap Net Income Loss
NetIncomeLoss
-14373000
CY2008 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
7944000
CY2008 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
750000
CY2008 rxii Adjustments To Divisional Equity Share Based Compensation Requisite Service Period Recognition Value
AdjustmentsToDivisionalEquityShareBasedCompensationRequisiteServicePeriodRecognitionValue
3824000
CY2012 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
13000
CY2012 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
6173000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
968000
CY2012 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
224000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-12880000
CY2012 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
-9500000
CY2012 us-gaap Preferred Stock Redemption Discount
PreferredStockRedemptionDiscount
9500000
CY2012 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
2865000
CY2012 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-3315000
CY2012 rxii Adjustments To Additional Paid In Capital Expenses Paid By Parent Company
AdjustmentsToAdditionalPaidInCapitalExpensesPaidByParentCompany
699000
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
112956911 shares
rxii Combined Results Of Operation Of Cumulative Period Since Inception
CombinedResultsOfOperationOfCumulativePeriodSinceInception
46176000
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 dei Document Type
DocumentType
10-Q
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001533040
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013Q1 dei Trading Symbol
TradingSymbol
RXII
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
RXI PHARMACEUTICALS CORP
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2013Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2013Q1 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
3547000
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13771000
CY2013Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.65
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-54000
CY2013Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
731000
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
194882870000 shares
CY2013Q1 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
473000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
628000
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
14516000
CY2013Q1 us-gaap Debt Instrument Maturity Date Description
DebtInstrumentMaturityDateDescription
Three months or less
CY2013Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
12250000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14394000
CY2013Q1 us-gaap Revenue From Grants
RevenueFromGrants
53000
CY2013Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
628000
CY2013Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
3000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-14397000
CY2012Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
40000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
676000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15644000
CY2013Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
3547000
CY2013Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2013Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
7.50
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-110000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
14447000
CY2013Q1 us-gaap Revenues
Revenues
53000
CY2013Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15647000
CY2013Q1 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
3547000
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17944000
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
787656384 shares
CY2013Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Uses of estimates in preparation of financial statements</i></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</font></p> </div>
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
359000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-50000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15647000
CY2013Q1 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
3377000
CY2013Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1096000
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1128000
CY2013Q1 rxii Net Proceeds From Issuance Of Common Stock
NetProceedsFromIssuanceOfCommonStock
15600000
CY2013Q1 rxii Research And Development Employee Stock Based Compensation Expense
ResearchAndDevelopmentEmployeeStockBasedCompensationExpense
373000
CY2013Q1 rxii Research And Development Non Employee Stock Based Compensation Expense
ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense
52000
CY2013Q1 rxii General And Administrative Employee Stock Based Compensation
GeneralAndAdministrativeEmployeeStockBasedCompensation
203000
CY2013Q1 rxii Distribution Ratio Description
DistributionRatioDescription
One share of RXi common stock for every one share of Galena common stock.
CY2013Q1 rxii Research And Development Intangibles Purchased From Others
ResearchAndDevelopmentIntangiblesPurchasedFromOthers
12250000
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-1926000
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
751000
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1154000
CY2012Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-19000
CY2012Q1 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
674000
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
214000
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-199000
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1905000
CY2012Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
12000
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1010000
CY2012Q1 us-gaap Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
522000
CY2012Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-128000
CY2012Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-22000
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
1905000
CY2012Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
500000
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1926000
CY2012Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6000
CY2012Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
360000
CY2012Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1017000
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1209000
CY2012Q1 rxii Research And Development Employee Stock Based Compensation Expense
ResearchAndDevelopmentEmployeeStockBasedCompensationExpense
38000
CY2012Q1 rxii Research And Development Non Employee Stock Based Compensation Expense
ResearchAndDevelopmentNonEmployeeStockBasedCompensationExpense
99000
CY2012Q1 rxii General And Administrative Employee Stock Based Compensation
GeneralAndAdministrativeEmployeeStockBasedCompensation
77000

Files In Submission

Name View Source Status
0001193125-13-220846-index-headers.html Edgar Link pending
0001193125-13-220846-index.html Edgar Link pending
0001193125-13-220846.txt Edgar Link pending
0001193125-13-220846-xbrl.zip Edgar Link pending
d521143d10q.htm Edgar Link pending
d521143dex101.htm Edgar Link pending
d521143dex311.htm Edgar Link pending
d521143dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxii-20130331.xml Edgar Link completed
rxii-20130331.xsd Edgar Link pending
rxii-20130331_cal.xml Edgar Link unprocessable
rxii-20130331_def.xml Edgar Link unprocessable
rxii-20130331_lab.xml Edgar Link unprocessable
rxii-20130331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending